Host defenses against zygomycetes

Emmanuel Roilides; Dimitrios P. Kontoyiannis; Thomas J. Walsh

doi:10.1093/cid/cir869

Host defenses against zygomycetes

Emmanuel Roilides, Dimitrios P. Kontoyiannis, Thomas J. Walsh

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Mucormycosis is a devastating disease and can occur in patients with a variety of risk factors, the most important of which are immunosuppression, anatomic barrier breakdown, iron overload, and hyperglycemia/acidosis. Similarly to what occurs with Aspergillus, the host stimulates an innate immune response against the challenging sporangiospores and invading hyphae of Zygomycetes. This article discusses the host defense to different Zygomycetes, its augmentation, and its subsequent impact on the outcome of mucormycosis.

Original language	English (US)
Pages (from-to)	S61-S66
Journal	Clinical Infectious Diseases
Volume	54
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1093/cid/cir869
State	Published - Feb 1 2012
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/cir869

Cite this

@article{9d7893168e524c53a109206401727fdf,

title = "Host defenses against zygomycetes",

abstract = "Mucormycosis is a devastating disease and can occur in patients with a variety of risk factors, the most important of which are immunosuppression, anatomic barrier breakdown, iron overload, and hyperglycemia/acidosis. Similarly to what occurs with Aspergillus, the host stimulates an innate immune response against the challenging sporangiospores and invading hyphae of Zygomycetes. This article discusses the host defense to different Zygomycetes, its augmentation, and its subsequent impact on the outcome of mucormycosis.",

author = "Emmanuel Roilides and Kontoyiannis, {Dimitrios P.} and Walsh, {Thomas J.}",

note = "Funding Information: Potential conflicts of interest. E. R. has received grant support from Pfizer, Gilead, Enzon, Schering, and Wyeth; served as a consultant for Schering, Gilead, Astellas, and Pfizer; and served on the speakers bureaus for Gilead, Cephalon, Pfizer, Wyeth, Schering, Merck, Aventis, and Astellas. D. P. K. has received research support and honoraria from Schering-Plough, Pf izer, Astella Pharma, Enzon Pharmaceuticals, and Merck. T. J. W. has received grant support from Novartis, Astellas; Consultation: Novartis, Vestagen, iCo, Trius, Astellas, Sigma Tau, and Draius.",

year = "2012",

month = feb,

day = "1",

doi = "10.1093/cid/cir869",

language = "English (US)",

volume = "54",

pages = "S61--S66",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Host defenses against zygomycetes

AU - Roilides, Emmanuel

AU - Kontoyiannis, Dimitrios P.

AU - Walsh, Thomas J.

N1 - Funding Information: Potential conflicts of interest. E. R. has received grant support from Pfizer, Gilead, Enzon, Schering, and Wyeth; served as a consultant for Schering, Gilead, Astellas, and Pfizer; and served on the speakers bureaus for Gilead, Cephalon, Pfizer, Wyeth, Schering, Merck, Aventis, and Astellas. D. P. K. has received research support and honoraria from Schering-Plough, Pf izer, Astella Pharma, Enzon Pharmaceuticals, and Merck. T. J. W. has received grant support from Novartis, Astellas; Consultation: Novartis, Vestagen, iCo, Trius, Astellas, Sigma Tau, and Draius.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Mucormycosis is a devastating disease and can occur in patients with a variety of risk factors, the most important of which are immunosuppression, anatomic barrier breakdown, iron overload, and hyperglycemia/acidosis. Similarly to what occurs with Aspergillus, the host stimulates an innate immune response against the challenging sporangiospores and invading hyphae of Zygomycetes. This article discusses the host defense to different Zygomycetes, its augmentation, and its subsequent impact on the outcome of mucormycosis.

AB - Mucormycosis is a devastating disease and can occur in patients with a variety of risk factors, the most important of which are immunosuppression, anatomic barrier breakdown, iron overload, and hyperglycemia/acidosis. Similarly to what occurs with Aspergillus, the host stimulates an innate immune response against the challenging sporangiospores and invading hyphae of Zygomycetes. This article discusses the host defense to different Zygomycetes, its augmentation, and its subsequent impact on the outcome of mucormycosis.

UR - http://www.scopus.com/inward/record.url?scp=84855874847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855874847&partnerID=8YFLogxK

U2 - 10.1093/cid/cir869

DO - 10.1093/cid/cir869

M3 - Article

C2 - 22247447

AN - SCOPUS:84855874847

SN - 1058-4838

VL - 54

SP - S61-S66

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - SUPPL. 1

ER -

Host defenses against zygomycetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this